Since topiramate was approved in 1995 (1996 in the United States), several case reports have been published addressing its ocular side effects.1-4⇓⇓⇓ Pathologic findings include secondary angle-closure glaucoma, transient myopia, and uveal effusions. Patients experience acute visual disturbances, headache, and bilateral bulbar pain without any clinical signs of drug intoxication. The risk of these adverse reactions has been addressed in topiramate’s US labeling since 2001.5 We report a case of fully reversible bilateral glaucoma and acute myopia associated with oral topiramate therapy. A 23-year-old woman presented to her eye specialist with a 4-day history of progressive blurred vision, bilateral eye pain, and retrobulbar headache, exacerbated by eye movements. Six days prior to the onset of symptoms she started topiramate (50 mg daily) for adjunctive therapy of partial-onset seizures. Her other medication included lamotrigine and levetiracetam, both …